DGAP-News: MeVis Medical Solutions AG

DGAP-News: MeVis Medical Solutions AG: MeVis publishes figures for fiscal year 2015 and guidance for 2016

DGAP-News: MeVis Medical Solutions AG / Key word(s): Final Results MeVis Medical Solutions AG: MeVis publishes figures for fiscal year 2015 and guidance for 2016

22.04.2016 / 13:30 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Revenues increased by 22 %, earnings per share of EUR 3.76 (after EUR 2.16 in 2014)

- Revenues increased by 22 % year on year to EUR 16.0 m

- Earnings before interest an taxes (EBIT) increased by EUR 0.6 m to EUR 4.5 m

- Net income rose by EUR 3.0 m to EUR 6.7 m

- Liquidity increased by EUR 8.1 m to EUR 25.6 m

- Guidance for 2016:

- Decline in revenues to EUR 14.5 m to EUR 15.0 m

- Decrease of EBIT to EUR 2.5 m to EUR 3.0 m

Bremen, April 22, 2016 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its figures for fiscal year 2015.

Revenues in 2015 increased significantly by 22 % (EUR 2.9 m) to EUR 16.0 m. However, the largest part of this increase (EUR 2.3 m) was attributable to a stronger US dollar; In addition, services made a EUR 0.5 m contribution to the revenue increase due, first and foremost, to the new cooperation agreement with Hologic. As a result, the licensing and maintenance business grew by just EUR 0.1 m when adjusted for currency effects.

The increase in revenues is almost entirely attributable to the Digital Mammography segment, where sales to Hologic rose from EUR 9.8 m to EUR 12.6 m, whereas revenues in the Other Diagnostics segment increased only slightly, from EUR 3.3 m to EUR 3.4 m, despite the stronger US dollar.

Operating costs rose in 2015. Staff costs increased, as planned, by EUR 0.4 m to EUR 7.4 m, and other operating expenses rose by EUR 0.7 m to EUR 2.7 m, mainly on account of higher legal and consulting costs in connection with the takeover offer and the domination and profit and loss transfer agreement with VMS Deutschland Holdings GmbH.

Development costs were capitalized for the last time in the fourth quarter of 2014. As a result, they no longer contributed to the result in 2015, following income of EUR 1.2 m in 2014.

Depreciation and amortization increased slightly by EUR 0.2 m to EUR 1.9 m in 2015.

For the fiscal year this led to a EUR 0.6 m increase in EBIT (earnings before interest and taxes) to EUR 4.5 m, which corresponds to a still attractive EBIT margin of 28 % (prev. year 30 %).

The financial result declined by EUR 0.6 m year on year to EUR 0.5 m, mainly due to the deterioration in the result from exchange rate differences.

Tax income amounted to EUR 1.8 m in 2015 (in 2014 tax expenses of EUR 1.2 m). The reason for this rise was the release of deferred tax liabilities due to the fiscal unity for income tax purposes becoming effective in 2016.

As a result, after-tax earnings rose strongly from EUR 3.7 m to EUR 6.7 m, which is equivalent to undiluted earnings per share of EUR 3.76 (after EUR 2.16 in 2014).

In the fiscal year, cash and cash equivalents again saw a strong increase, of EUR 8.1 m to EUR 25.6 m, on the back of a strong operating development and the disposal of treasury stock to VMS Deutschland Holdings GmbH for EUR 1.7 m.

"2015 was economically for us another very successful year. Our dependency on Hologic has, however, increased even further, which is reflected in a share of 78 % of total revenues in the past fiscal year." said Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG." He added: "For 2016, we expect a slight decline in revenues to EUR 14.5 m to EUR 15.0 m, mainly from the existing business with Hologic. For most of the year 2017 this existing business should still continue, although we expect a significant decline in business with Hologic by the end of 2017 and in 2018."

"We are facing bigger challenges in the future. In addition to the very large dependency on Hologic, the market for our products for lung cancer screening has not been developed as quickly as widely expected. Moreover, we continue to see a trend in the market toward fully integrated applications of the PACS suppliers, making it increasingly difficult for us to convince clinical end users of the added value of our dedicated specialized software solutions." added Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. "We remain confident that we are well prepared to meet future challenges. Contributing to this are mainly our experienced, highly qualified employees and the perspective cooperation with Varian Medical Systems."

The interim financial statement for the first quarter 2016 will be published on May 24, 2016.

---------------------------------------------------------------------------

22.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English Company: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: ir@mevis.de Internet: http://www.mevis.de ISIN: DE000A0LBFE4 WKN: A0LBFE Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News Service ---------------------------------------------------------------------------

456921 22.04.2016